An evaluation of the pharmacotherapy for interstitial cystitis

  title={An evaluation of the pharmacotherapy for interstitial cystitis},
  author={Laura L. Giusto and Patricia M. Zahner and Daniel A. Shoskes},
  journal={Expert Opinion on Pharmacotherapy},
  pages={1097 - 1108}
ABSTRACT Introduction: Interstitial cystitis (IC) and bladder pain syndrome (BPS) are chronic conditions that can be debilitating for patients. There is no consensus as to their etiology, and there are many proposed treatment algorithms. Oftentimes multimodal therapy, such as combining behavioral modification and physical therapy alongside pharmacotherapies, will be utilized. With the various treatment options available to patients and providers, there is an ever-growing need to implement… 
Pharmacotherapy for Interstitial Cystitis/Bladder Pain Syndrome
Current literature regarding pharmacotherapy treatment strategies available for the management of interstitial cystitis/bladder pain syndrome (IC/BPS) will be addressed including oral, transdermal,
An update on treatment options for interstitial cystitis
Only further investigation on the etiopathogenetic mechanisms, taking into account the differences among subgroups, and the interaction between central and peripherical factors may allow providing a real improvement in the treatment and management of patients with IC/BPS.
Treatment of Interstitial Cystitis/Bladder Pain Syndrome: A Contemporary Review
Interstitial cystitis/bladder pain syndrome (IC/BPS) is a debilitating condition affecting approximately 3% of the female population. IC/BPS is defined as an unpleasant sensation (pain, pressure,
Use of Intravesical Injections of Platelet-Rich Plasma for the Treatment of Bladder Pain Syndrome: A Comprehensive Literature Review
New evidence suggests that treatment with intravesical PRP could improve urothelial regeneration and reduces chronic inflammation in BPS/IC, modifying the clinical history of its pathology.
Systemic Therapy for Bladder Pain Syndrome/Interstitial Cystitis (BPS/IC): Systematic Review of Published Trials in the Last 5 Years
The interpretation of BPS/IC trial results is not straightforward especially when compared to other pathologies, due to difficulty in characterizing and phenotyping patients, and both positive and inconclusive trials should motivate peers to continue the search for novel therapies in this condition.
Efficacy and safety comparison of pharmacotherapies for interstitial cystitis and bladder pain syndrome: a systematic review and Bayesian network meta-analysis
Comparing the clinical efficacy and safety of pharmacological interventions for interstitial cystitis and bladder pain syndrome with direct and indirect evidence from randomized trials found cyclosporine A might be superior to other pharmacological treatments in efficacy.
Therapeutic management of Interstitial Cystitis/ Bladder Pain Syndrome in humans
The AUA selected this definition as it reduces the risk of delaying treatment unlike other definitions that require a waiting period of 6 months or longer before treatment starts. For example, the
Chondroitin Sulfate and Hyaluronic Acid Perfusion for Interstitial Cystitis/Bladder Pain Syndrome A Systematic Review and Meta-Analysis
  • Xiang Xiao, Huan Deng, +8 authors C. Qu
  • Science Insights
  • 2021
Currently, no suitable delivery methods are available for the drugs to interstitial cystitis/ bladder pain syndrome (IC/BPS). Herein we systematically evaluated the therapeutic effects of
Comparative effectiveness and safety of intravesical instillation treatment of interstitial cystitis/bladder pain syndrome: a systematic review and network meta-analysis of randomized controlled trials
A large variety of agents are available for intravesical instillation treatment of interstitial cystitis/bladder pain syndrome and resiniferatoxin (0.1 μM) is more effective at ICPI and ICSI improvement than other agents, suggesting more well-designed randomized controlled trials with a large sample size directly comparing the efficacy and safety of those agents are in need.


Management of Interstitial Cystitis/Bladder Pain Syndrome with Tricyclic Antidepressants
The tricyclic antidepressant amitriptyline (Elavil) has become a staple of oral treatment of IC/BPS (interstitial cystitis/bladder pain syndrome), and there is uncertainty in the balance between benefits and risks/burden of the treatment.
Complementary and alternative therapies as treatment approaches for interstitial cystitis.
The management of interstitial cystitis (IC) is predominantly the reduction of the symptoms of frequency, urgency, and pain. Multimodal treatment approaches for IC are helpful in customizing therapy
Treatment effect of cyclosporine A in patients with painful bladder syndrome/interstitial cystitis: A systematic review.
The evidence from the studies implied that treatment of CyA can result in a long-term benefit in patients of PBS/IC; however, further evidence is required to verify this.
Results of treatment of refractory interstitial cystitis with intravesical hyaluronic acid.
The results of this limited study were satisfactory in the group of responsive patients, who had no relapses during the observation period of 6 months, and the intravesical administration of hyaluronic acid was well tolerated in all cases.
Treatment of interstitial cystitis with a quercetin supplement.
Oral therapy with the quercetin supplement Cysta-Q was well tolerated and provided significant symptomatic improvement in patients with IC, and larger, randomized, placebo-controlled trials appear warranted based on these preliminary open-label results.
Multimodal therapy for painful bladder syndrome / interstitial cystitis: pilot study combining behavioral, pharmacologic, and endoscopic therapies.
A pilot multimodal protocol of behavioral modification, pharmacologic therapy and endoscopic hydrodistention demonstrated a significant progressive improvement in PBS/IC quality of life scores, compared to a pre-treatment baseline.
Clinical phenotyping in chronic prostatitis/chronic pelvic pain syndrome and interstitial cystitis: a management strategy for urologic chronic pelvic pain syndromes
A six-domain phenotype is proposed, which can classify patients clinically and can direct the selection of therapy in the most evidence based multimodal manner, and is flexible and responsive to new biomarkers and therapies as their utility and efficacy are proven.